Precision BioSciences, Inc. · NASDAQ:DTIL
Precision BioSciences — Investor Presentation (November 2026)
76 slides from Precision BioSciences's investor presentation, November 2026
Slide 1: Corporate Presentation
Corporate Presentation November 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,
Slide 3: ARCUS: Precision's Proprietary Gene Editing Platform
ARCUS: Precision’s Proprietary Founded in 2006 and dedicated Gene Editing Platform to developing novel therapeutics designed with goal 〉 ARCUS wholly owned by Precision BioSciences of curing difficult-to-treat 〉 Derived from the homing endonuclease I-CreI found in green algae diseases with high unme
Slide 4: Setting the Stage for Viral Cure
Setting the Stage for Viral Cure
Slide 5: PBGENE-HBV: Designed for Viral Cure Through cccDNA Elimination
The Problem: cccDNA is the root cause of chronic hepatitis B Designed for Viral Cure All other therapies suppress Through cccDNA Elimination: while preserving cccDNA: ASO, NUCs, siRNA, CAMs, entry PBGENE-HBV inhibitors, epigenetic modifiers, mAbs, immune therapies ASO, antisense oligonucleotide; CAM
Slide 6: Since May 2026 at EASL: Treatment Effect in 100% of Patients
Since May 2026 at EASL… Treatment Effect in 100% of Patients 〉 38 administrations, 16 patients From the Liver to the Blood → Advent of pgRNA blood biomarker 〉 100% of patients with durable pgRNA undetectable Evidence of Direct Elimination of cccDNA in Biopsy 〉 1log reduction Safety Characterization
Slide 7: Late-Breaking AASLD Data: cccDNA Elimination at 0.4 mg/kg
Late-Breaking Oral Presentation at AASLD Demonstrating cccDNA Elimination at 0.4 mg/kg Reproducible Liver Biopsies 11 Patients with pgRNA Loss, with ≥1log cccDNA Elimination Durability in 100% with ≥6 Months Evaluable 1 Pt 6 0.4 mg/kg Pt 7 0.8 mg/kg Normalized cccDNA transcripts Pt 9 0.8 mg/kg 0.8 P
Slide 8: 100% pgRNA Loss in the First HBeAg+ Patient
Late-Breaking Oral Presentation at AASLD Demonstrating cccDNA Elimination at 0.4 mg/kg 6000 Groundbreaking Dose 1 5000 100% Loss HBV pgRNA (C/mL) 4000 of pgRNA in the 3000 First HBeAg+ Patient 2000 100% pgRNA Loss in the First HBeAg+ Patient 1000 Dose 2 Limit of 0 0 Detection -14 AASLD 0 14 28 42 56
Slide 9: Phase 1 ELIMINATE-B Trial Success… PBGENE-HBV Moves to Phase 2
Phase 1 Eliminate B Trial Success… PBGENE-HBV Moves to Phase 2 9
Slide 10: PBGENE-HBV: Eliminating cccDNA to Drive Viral Cure
PBGENE-HBV: Eliminating cccDNA to Drive Viral Cure
Slide 11: cccDNA Is the Only Source of New Infectious Particles
cccDNA Is the Only Source of New Infectious Particles Known as HBV DNA The Trinity of HBV Infection cccDNA makes pgRNA makes HBV DNA cccDNA in liver pgRNA in blood HBV DNA in blood (Infectious particles) Therefore, cccDNA Elimination is the Only Path to Viral Cure cccDNA, covalently closed circular
Slide 12: While on NUCs, Patients Have Undetectable HBV DNA
While on NUCs, Patients in ELIMINATE-B Have Undetectable HBV DNA NUCs prevent conversion of pgRNA to HBV DNA NUC cccDNA in liver pgRNA in blood HBV DNA in blood (Infectious particles) cccDNA is only present in the liver and requires biopsies Therefore, pgRNA is the biomarker in the blood for HBV DNA
Slide 13: From Decades to Days: PBGENE-HBV Eliminates cccDNA
From Decades to Days: PBGENE-HBV Eliminates cccDNA, Potentially Changing the Natural History of Chronic Hepatitis B Enabling a Viral Cure TARGET BIOMARKER ENDPOINT PBGENE-HBV cccDNA in liver pgRNA in blood HBV DNA in blood (Infectious particles) By directly eliminating cccDNA, PBGENE-HBV is designed
Slide 14: Phase 1 ELIMINATE-B Data Support Advancement to Phase 2
Phase 1 ELIMINATE-B Data Support Advancement to Phase 2
Slide 15: Patient Baseline Characteristics (n=25)
Patient Baseline Characteristics (n=25) Number Percent Sex Male 20 80 Caucasian 7 28 Ethnicity/ Asian 16 64 Race Native Hawaiian or 2 8 Other Pacific Islander Mean Range Age (years) 48 34-64 Time on NUCs (years) 11.8 1.2-29.1 Baseline pgRNA (C/mL) 257 TND-5,750 Baseline HBsAg (IU/mL) 4203 178-34,489
Slide 16: Comprehensive Evaluation of PBGENE-HBV Across 4 Dose Levels
Comprehensive Evaluation of PBGENE-HBV: 59 Administrations in 25 Patients Across 4 Dose Levels 0.2 mg/kg 0.4 mg/kg 0.65 mg/kg 0.8 mg/kg HBV, hepatitis B virus; Pt; patient. Data cutoff: September 28, 2026. 16
Slide 17: Extensive Experience with the Go-Forward Dose 0.4 mg/kg
Extensive Experience with the Go-Forward Dose 0.4 mg/kg PBGENE-HBV 0.2 mg/kg 0.4 mg/kg 0.65 mg/kg 0.8 mg/kg 3 pts 13 pts 6 pts 3 pts 9 admins 30 admins 13 admins 7 admins Achieved Target Product Profile for PBGENE-HBV as Low as 0.4 mg/kg HBV, hepatitis B virus; Pt; patient. Data cutoff: September 28
Slide 18: PBGENE-HBV Drives Durable pgRNA Undetectable Through cccDNA Elimination
NEW AASLD DATA: PBGENE-HBV Drives Ongoing Durable pgRNA Undetectable Through cccDNA Elimination NUC cccDNA pgRNA HBV DNA Patient 6 0.4 mg/kg Patient 7 0.8 mg/kg Patient 9 0.8 mg/kg Patient 10 0.4 mg/kg Patient 12 0.4 mg/kg Green Patient 14 0.65 mg/kg is Good Patient 15 0.65 mg/kg Patient 16 0.65 mg/
Slide 19: Durable pgRNA Undetectable at 0.4 mg/kg
NEW AASLD DATA: PBGENE-HBV Drives Ongoing Durable pgRNA Undetectable Through cccDNA Elimination NUC cccDNA pgRNA HBV DNA Patient 6 0.4 mg/kg Patient 10 0.4 mg/kg Patient 12 0.4 mg/kg Patient 18 0.4 mg/kg pgRNA Loss in 100% of Patients at 0.4 mg/kg Patient 19 0.4 mg/kg HBeAg+ Patient 21 0.4 mg/kg Pre
Slide 20: HBeAg Positive Patients: Greatest cccDNA Burden
HBeAg Positive Patients: Difficult to Treat with Greatest cccDNA Burden The median cccDNA levels were 2-3log higher in HBeAg+ patients compared to HBeAg- patients. — Werle-Lapostolle et al, 2004, Gastroenterology
Slide 21: Viral Cure Hardest in HBeAg Positive Patients
A Viral Cure is Hardest to Achieve in HBeAg Positive Patients Because They Have Logarithmically More cccDNA and Therefore More pgRNA HBeAg Positive HBeAg Negative cccDNA in liver pgRNA in blood cccDNA in liver pgRNA in blood cccDNA, covalently closed circular DNA; HBeAg, hepatitis B e antigen; pgRNA
Slide 22: Eliminating cccDNA at 0.4 mg/kg Leads to 100% Loss of pgRNA
NEW AASLD DATA: Eliminating cccDNA at 0.4 mg/kg Leads to 100% Loss of pgRNA in First HBeAg+ Patient 6000 Dose 1 HBV pgRNA: Patient 19 100% Loss of pgRNA in 5000 First HBeAg 4000 Positive Patient HBV pgRNA (C/mL) 3000 2000 1000 Dose 2 00 Limit of Detection -14 0 14 28 42 56 70 Days from First Dose pg
Slide 23: Liver Biopsy Evidence Supports cccDNA Elimination at 0.4 mg/kg
Liver Biopsy Evidence Supports cccDNA Elimination at 0.4 mg/kg
Slide 24: Biopsy Data Reproduced Potent cccDNA Elimination at 0.4 mg/kg
NEW AASLD DATA: Biopsy Data Reproduced Potent cccDNA Elimination at 0.4 mg/kg Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 Dose 4 Patient Patient 5 First Second 6 First Second Biopsy Biopsy Biopsy Biopsy 1 1 Normalized cccDNA transcripts Normalized cccDNA transcripts 0.8 0.8 10-fold 35-fold (1-log) (1.
Slide 25: Secondary Biomarker HBsAg: Every Patient Experienced Treatment Effect
Secondary Biomarker HBsAg: Every ELIMINATE-B Patient Experienced Treatment Effect with PBGENE-HBV (n=24 evaluable at time of data cutoff)
Slide 26: Substantial HBsAg Declines in All Patients
NEW AASLD DATA: Substantial HBsAg Declines Indicative of cccDNA Elimination in All Patients With or Without pgRNA 0.2 mg/kg 0.4 mg/kg 0.65 mg/kg 0.8 mg/kg 0% Max Decline in HBsAg From Baseline (percentage) -10% -20% -30% -40% Significant maximal HBsAg -50% declines across all patients -60% (n=24) -7
Slide 27: 0.4 mg/kg Sufficient for Maximal Efficacy and Durability
NEW AASLD DATA: 0.4 mg/kg is Sufficient for Maximal Efficacy & Durability 0.4 mg/kg 0.65 mg/kg 0.8 mg/kg 0% Max Decline in HBsAg From Baseline (percentage) -10% -20% -30% -40% Maximal HBsAg declines -50% observed as low as -60% 0.4 mg/kg -70% Only 1 dose administered -80% to date -90% -100% Durabili
Slide 28: PBGENE-HBV Safety Profile Executive Summary
PBGENE-HBV Safety Profile Executive Summary 〉 59 doses administered across 25 evaluable patients 〉 Primary Endpoint: No dose-limiting toxicities observed 〉 Most common adverse events are infusion-related reactions consistent with LNP effects, with onset and resolution within 24 hours of infusion 〉 C
Slide 29: Safety Profile: Therapeutic Window at 0.4 mg/kg
PBGENE-HBV Safety Profile: Clear Evidence of Therapeutic Window at 0.4 mg/kg 0.4 mg/kg 0.65 mg/kg 0.4 mg/kg Number of patients with AEsa: w/ current infusion protocol n=6 n=13 n=8 of 13 Grade 3 Hypotension 4 3b - Grade 3 and 4 ALT/AST lab abnormality 4 2 1 SAEs - - - 〉 Current Infusion Protocol: No
Slide 30: Phase 1 Efficacy Data Support 0.4 mg/kg as Go-Forward Dose
NEW AASLD DATA: Definitive Phase 1 Efficacy Data Support 0.4 mg/kg as Go-Forward Dose Groundbreaking Reproducible Liver Biopsies Durable pgRNA Loss 100% pgRNA Loss in with ≥1-log cccDNA Elimination ≥6 Months First HBeAg+ Patient 1 6000 Dose 1 Pt 6 0.4 mg/kg Normalized cccDNA transcripts Pt 7 0.8 mg/
Slide 31: Go-Forward Phase 2 Dose of 0.4 mg/kg Selected
Go-Forward Phase 2 Dose of 0.4 mg/kg for PBGENE-HBV: Selected Based on Compelling Evidence Efficacy: 〉 100% of patients experienced a treatment effect with PBGENE-HBV (n=24) 〉 92% (11/12) of patients achieved pgRNA loss to undetectable − Last remaining patient had 95% pgRNA reduction at data cutoff
Slide 32: What's Next: PBGENE-HBV Moves to Phase 2 Global Expansion
What’s Next: PBGENE-HBV Moves to Phase 2 Global Expansion
Slide 33: ELIMINATE-B Trial Moves to Phase 2 Expansion
Establishing PBGENE-HBV as the Foundation of Treatment in HBV: ELIMINATE-B Trial Moves to Phase 2 Expansion Viral Cure Monotherapy cccDNA Elimination PBGENE-HBV 0.4 mg/kg Q8W Endpoint: Undetectable HBV DNA off therapy Cessation of Nucleos(t)ide Analogs Functional Cure Suppression of viral infection
Slide 34: PBGENE-HBV Goal to Improve Upon Cure Rates in CHB
PBGENE-HBV Goal to Improve Upon Cure Rates in CHB Monotherapy + Combination with ASO Viral Cure Functional Cure Complete cccDNA elimination in the liver Suppression of viral infection FDA Endpoint: Undetectable HBV DNA for 6 • FDA Endpoint: Undetectable HBV DNA and HBsAg months (off therapy includin
Slide 35: Rationale for Potential Combination
Rationale for Potential Combination
Slide 36: Bepirovirsen Most Effective with Lower Viral Burden
Bepirovirsen Most Effective in Patients with Lower Viral Burden; 19% Functional Cure Rate in B-Well 1 and B-Well 2 Studies Functional Cure Rates in B-Well 1 and B-Well 2 Phase 3 Studies Higher Viral Burden Lower Viral Burden HBeAg+ HBsAg ≤3000 IU/mL HBsAg ≤1000 IU/mL 8% 19% 26% HBeAg, hepatitis B e
Slide 37: Synergy of PBGENE-HBV + ASO in HBV Mouse Model
Synergy of PBGENE-HBV + ASO in HBV Mouse Model Drove Deeper Reductions in HBV DNA and HBsAg Improved Depth and Durability of HBV DNA HBV Transgenic Mouse Model Treated and HBsAg Declines with PBGENE-HBV + ASO with ASO alone or PBGENE-HBV + ASO HBV DNA HBsAg 〉 Single dose of PBGENE-HBV 0 〉 Finite cou
Slide 38: ELIMINATE-B Phase 2 Expansion Schema
Establishing PBGENE-HBV as the Foundation of Treatment in HBV: ELIMINATE-B Trial Moves to Phase 2 Expansion Monotherapy Viral Cure cccDNA Elimination NUC-Only Stop NUC Endpoint: Undetectable HBV DNA PBGENE-HBV off therapy 0.4 mg/kg Q8W + NUC Sequential ASO/bepirovirsen* Functional Cure Suppression o
Slide 39: FUNCTION-DMD Clinical Momentum Continues with PBGENE-DMD
FUNCTION-DMD Clinical Momentum Continues with PBGENE-DMD
Slide 40: PBGENE-DMD Designed to Provide Durable Functional Improvement
PBGENE-DMD Designed to Provide Durable Functional Improvement for 60% of Patients with DMD PBGENE-DMD: A single AAV encodes 2 ARCUS proteins designed to permanently edit a patient’s own DNA sequence, resulting in naturally expressed, functional dystrophin Up to 60% ARCUS 1 ARCUS 2 of patients have p
Slide 41: Preclinical Data Supports Potential of PBGENE-DMD
Preclinical Data Supports Potential of PBGENE-DMD to Provide Therapeutic Benefit Preclinical Data from Humanized DMD Mouse Model Demonstrates >5% Dystrophin Protein Expression Heart Calf 15 30 Based on natural history data, Dystrophin Restoration (%) Dystrophin Restoration (%) 25 as little as 5% exp
Slide 42: Phase 1/2 Study Designed for Safety and Speed
Phase 1/2 Study Designed for Safety and Speed Clinical Trial Identifier: NCT07429240 Inclusion criteria • Male age 2-7 • Stable IMR ≥12 weeks • Able to complete age-appropriate • DMD with mutations in exons 45-55 • Up-to-date vaccines motor testing assessments Part 1: Part 2: Initial Safety Cohort (
Slide 43: PBGENE-DMD Continues to Advance in FUNCTION-DMD Study
PBGENE-DMD Continues To Advance In FUNCTION-DMD Study 1st patient successfully dosed August 2026 〉 No serious adverse events, no adverse events of special interest (including no TMA, myocarditis, or acute liver injury) DSMB has reviewed patient 1 data through week 8 〉 No safety concerns identified 〉
Slide 44: Numerous Upcoming Catalysts in Next 12 Months
Precision BioSciences Has Numerous Upcoming Catalysts in Next 12 Months Key Expected Inflection Points Through 2027 PBGENE-HBV LNP Program PBGENE-DMD AAV Program AASLD Late-Breaking Oral Data Update 2026 Q4 & Phase 2 Study Plan Safety Update from Initial Patients 〉Initiate ELIMINATE-B2 Global Ph2 St
Slide 45: Expected Cash Runway into Q4 2029
Expected Cash Runway into Q4 2029: Funds Both Clinical Programs Through Key Next Stage Inflection Points PBGENE-HBV 〉 Funds PBGENE-HBV through global Phase 2 study (ELIMINATE-B2) 〉 Open Label Data results: 〉 PBGENE-HBV monotherapy viral cure 〉 PBGENE-HBV with bepirovirsen (ASO) for functional cure P
Slide 46: Leadership Team Driving Programs Through Next Clinical Milestones
Precision BioSciences Leadership Team Driving Programs Through Next Clinical Milestones Michael Amoroso Cassie Gorsuch, Ph.D. Alex Kelly Naresh Tanna Dario Scimeca Since Oct 2021 Since June 2016 Since Oct 2020 Since Jan 2022 Since June 2019 President & Chief Scientific Officer Chief Operating Office
Slide 47: Appendix
PRECISION BIOSCIENCES Appendix my
Slide 48: PBGENE-HBV Positioned to Impact More Patients than Other Gene Therapies
PBGENE-HBV Positioned to Potentially Impact More Patients cHBV than Other Gene Therapy Programs SCD and Transfusion- Dependent Beta-Thal Other Gene Therapy Programs WW Prevalence 25M Size based on worldwide prevalence wAMD 300M 20M US Prevalence HeFH Up to 2.4M PiZ-AATD 8M ATTRv-PN (Lung and DMD Liv
Slide 49: Chronic Hepatitis B Multi-Billion Dollar Market Opportunity
Chronic Hepatitis B Multi-Billion Dollar Market Opportunity: Large patient population currently on non-curative treatment options Ch >300 Million US Market Opportunity of ~$10 Billion1 cHBV infections globally Driven by the drug-treated patient population today with total global aggregate revenue es
Slide 50: Phase 2 Study Endpoints Aligned to HBV Regulatory Guidance
Phase 2 Study Endpoints Aligned to Current HBV Regulatory Guidance GUIDANCE DOCUMENT Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment APRIL 2022 New finite duration therapies could be evaluated in clinical trials using any of the following efficacy endpoints: ● Sustained suppressi
Slide 51: PBGENE-HBV Directly Eliminates cccDNA; Other Therapies Suppress
PBGENE-HBV Directly Eliminates cccDNA; All Other Therapies Suppress While Preserving cccDNA Targeting the root source of CHB ANTISENSE NUCLEOS(T)IDE ANALOGS PBGENE- OLIGONUCLEOTIDES CAPSID ASSEMBLY HBV SMALL INTERFERING RNA MODULATORS HBV DNA HBV RNA Hepatocyte NUCLEIC ACID POLYMER HBsAg cccDNA Elim
Slide 52: Undetectable pgRNA Associated With Success of Stopping Nucleoside Analogs
Studies Demonstrate Undetectable pgRNA Is Associated With Success of Stopping Nucleoside Analogs and Increasing Probability of Cure Probability of Cure Stratifies on pgRNA 10X Increase in Probability of Cure With Non-quantifiable pgRNA pgRNA is a specific marker for cccDNA indicating viral load, whe
Slide 53: All EASL Patients Have Achieved 6+ Months of Durable pgRNA Loss
NEW AASLD DATA: ALL EASL Patients Have Achieved 6+ Months of Durable pgRNA Loss NUC cccDNA pgRNA HBV DNA Patient 6 0.4 mg/kg Patient 7 0.8 mg/kg Patient 9 0.8 mg/kg Patient 10 0.4 mg/kg Patient 12 0.4 mg/kg Pre-dose -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 Weeks from First Dose HBV pgRNA Dete
Slide 54: Lower cccDNA and Blood Biomarkers Track with Cure Rates
Lower cccDNA and Blood Biomarkers Track with Cure Rates 〉 Lower cccDNA in the liver is associated with significantly better odds of a sustained virologic response (adjusted odds ratio for log cccDNA was 5.3 [95% CI: 1.5-18.2, P = .009]) − Sung et al, 2005, Gastroenterology 〉 Functionally cured patie
Slide 55: HBsAg as a Secondary Biomarker
HBsAg as a Secondary Biomarker Derived From cccDNA and Integrated HBV DNA cccDNA- specific Biomarker cccDNA pgRNA HBV DNA (Infectious particles) Secondary Biomarker iDNA HBsAg pgRNA is the cccDNA-specific biomarker HBsAg is a secondary biomarker expected to be reduced with cccDNA elimination Back to
Slide 56: PBGENE-HBV Lowers Viral Burden, Potential to Increase Functional Cure Rate
Bepirovirsen Most Effective in Patients with Low Viral Burden; PBGENE-HBV Lowers Viral Burden and Potential to Increase Functional Cure Rate Bepirovirsen works at the RNA level, not the DNA level BEPI (ASO) PBGENE-HBV cccDNA pgRNA HBV DNA (Infectious particles) iDNA HBsAg 1 PBGENE-HBV Eliminates ccc
Slide 57: PBGENE-HBV Drove Durable HBsAg Declines at Doses ≥0.4 mg/kg
PBGENE-HBV Drove Durable HBsAg Declines at All Dose Levels ≥0.4 mg/kg 0% Mean HBsAg Decline at Data Cut -10% -20% -30% (percentage) -40% 2 of 3 patients at -50% 0.8 mg/kg received only 2 admins Durable HBsAg Declines at -60% All Dose Levels ≥0.4 mg/kg -70% -80% -90% -100% 0.40 0.65 0.80 Dose level (
Slide 58: PBGENE-HBV Safety Profile with CTCAE
PBGENE-HBV Safety Profile with CTCAE—Planned for Phase 2 CTCAE v6.0 –Planned for Phase 2 0.4 mg/kg 0.65 mg/kg 0.4 mg/kg Number of patients with AEsa: w/ current infusion protocol n=6 n=13 n=8 of 13 Grade 3 Hypotension - - - Grade 3 and 4 ALT/AST lab abnormality 4 2 1 SAEs - - - • An independent phar
Slide 59: Bepirovirsen Does Not Eliminate cccDNA
Bepirovirsen Does Not Eliminate cccDNA, Thus End of Treatment Response is Not Maintained End-of-Treatment Bepi + NUC Treatment Period NUC-Only Period Off-Therapy Period Response: 54% 24 weeks: 48 weeks: 72 weeks: End-of-Treatment Assess for Primary Response Stop NUCs Outcome 100 16 80 39 46 Off-Ther
Slide 60: Combination of PBGENE-HBV With Bepirovirsen Potentially Improves Depth and Durability
Combination of PBGENE-HBV With Bepirovirsen Potentially Improves Depth and Durability of Antiviral Activity Bepi + NUC Treatment Period NUC-Only Period Off-Therapy Period 24 weeks: 48 weeks: 72 weeks: End-of-Treatment Assess for Primary Response Stop NUCs Outcome 100 80 Goal of combination Participa
Slide 61: PBGENE-DMD
PBGENE-DMD a
Slide 62: Large Valuation Opportunity for Gene Therapy Drugs in DMD
Large Valuation Opportunity for Transformative Gene Therapy Drugs in DMD After receiving approval for its gene therapy Elevidys for DMD, Sarepta reached a peak market capitalization of ~$15.7B in June 2024. This was an increase from ~$3B in late 2017 when it received IND approval to initiate Phase 1
Slide 63: PBGENE-DMD Designed to Produce Near-Full-Length Dystrophin
PBGENE-DMD Designed to Produce a Near-Full-Length Dystrophin Protein, Demonstrated to be Functional in Humans H1 H2 H3 H4 Full-length ABD R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 CR CT Dystrophin Full-length Dystrophin Functional ABD H1 R1 R2 R3 H2 R4 R5
Slide 64: Near-Full-Length Dystrophin Has Known Function in Del45-55 Genotype
Near-Full-Length Dystrophin Protein Has Known Function in Individuals with Dystrophin Del45-55 Genotype Lifespan: Lifespan: • Early death in late teens or 20s • Can live into 60s-70s1-3 Clinical Presentation: Clinical Presentation: • Progressive muscle weakness leading • Asymptomatic or mild to loss
Slide 65: ~5% Dystrophin is Associated with Meaningful Clinical Benefit
~5% Dystrophin is Associated with Meaningful Clinical Benefit No dystrophin (0%) Group A (n=42) Residual dystrophin (0-5%) Group B (n=34) Residual dystrophin (>5%) Group C (n=14) 〉 ~5% dystrophin associated with prolonged ambulation beyond typical loss of ambulation time (~10–12 years) and linked to
Slide 66: PBGENE-DMD Reason-to-Believe: Bridging to Investigation in Humans
PBGENE-DMD Reason-to-Believe: Bridging to Investigation in Humans 66
Slide 67: PBGENE-DMD Increased Dystrophin Protein Levels Over Time
PBGENE-DMD Resulted in Increased Dystrophin Protein Levels Over Time, Exceeding Expected Therapeutic Threshold Heart Calf Quadriceps 15 30 25 Dystrophin Restoration (%) Dystrophin Restoration (%) Dystrophin Restoration (%) 25 20 10 20 15 15 10 5 10 5 5 0 0 0 Treated Treateddisease mice disease mice
Slide 68: Broad Distribution of Dystrophin Positive Cells
Broad Distribution of Dystrophin Positive Cells Across Skeletal, Cardiac, and Respiratory Muscles After PBGENE-DMD Treatment PBGENE-DMD Heart Calf Quadriceps Disease Model 75 80 60 Dystrophin positive cells (%) Dystrophin positive cells (%) Dystrophin positive cells (%) 60 60 45 45 40 30 30 20 15 15
Slide 69: Dystrophin Restoration in Respiratory Muscles of Early Juvenile Mice
PBGENE-DMD Achieves Therapeutic Dystrophin Restoration in Critical Respiratory Muscles of Early Juvenile DMD Mice Diaphragm Intercostals 10 25 30 Dystrophin protein restoration in Dystrophin Positive Fibers (%) early juvenile mice was up to Dystrophin Restoration (%) Dystrophin Restoration (%) 8 20
Slide 70: PBGENE-DMD Improved Muscle Function and Long-Term Durability
PBGENE-DMD Significantly Improved Muscle Function and Demonstrated Long-Term Durability Untreated Untreated PBGENE-DMD PBGENE-DMD Diseased Healthy (1x1014 vg/kg) (3x1013 vg/kg) 200% Normalized Force/BW to Untreated Disease 150% 100% 50% 0% 〉Improved muscle function observed from 3 to 6 months 〉Durab
Slide 71: Transduction in Nonhuman Primates Compared to Mice
PBGENE-DMD Demonstrated as Good as or Better Transduction in Nonhuman Primates Compared To Mice Suggesting Good Translatability Quad Gastroc NHP Diaphragm Mouse Heart 0 50 100 150 200 250 300 AAV Transduction (% of mouse) Strong Rationale for Go-Forward Dose Advancing in Humans AAV, adeno-associated
Slide 72: Nonclinical Data Support Safety and Efficacy of Clinical Dose
Nonclinical Data Support the Potential for Safety and Efficacy of the Clinical Dose SAFETY EFFICACY Evaluated in DMD mouse model and NHPs Evaluated in humanized DMD mouse model 〉 No adverse safety findings observed at the 〉 Similar levels of dystrophin protein restoration completion of 2 GLP studies
Slide 73: PBGENE-DMD Investigated at Lower or Equal Doses to Other AAV DMD Programs
PBGENE-DMD to be Investigated at Lower or Equal Doses to All Other AAV DMD Programs Approved or in Development Company Therapy Vector Dose level(s) tested PBGENE-DMD1 AAV9 1×10¹⁴ vg/kg SGT-0012* AAV9 Up to 2×10¹⁴ vg/kg SGT-0033 AAV9-derived 1×10¹⁴ vg/kg fordadistrogene movaparvovec AAV9 Up to 3×10¹⁴
Slide 74: Phase 1/2 Study Endpoints
Phase 1/2 Study Endpoints Clinical Trial Identifier: NCT07429240 Primary Endpoints 〉 Incidence, severity, and causality of TRAEs and SAEs from dosing through Week 104 〉 AEs and SAEs that occur or worsen after initiation of the investigational treatment Secondary Endpoints Exploratory Endpoints Biolo
Slide 75: Key Inclusion Criteria
Key Inclusion Criteria Category Inclusion Criteria Age / Sex Males, 2-7 years of age (inclusive) at time of consent Diagnosis Genetically confirmed DMD with mutations in exons 45-55 Able to complete age-appropriate motor testing assessments • Ages 2-<4: walk ≥10 meters Motor Ability • Ages 4-7: Must
Slide 76: Safety as Top Priority: Immune Modulation Regimen Strategy
Safety as Top Priority: Immune Modulation Regimen (IMR) strategy ensures monitoring and interventions are optimized to patient safety needs during 2 key safety risk periods Safety Mitigation: Preventing early and late serious immune complications. AAV therapies can trigger 2 predictable immune-relat
Precision BioSciences — Investor Presentation (November 2026) on 6ix